Closed · W81XWH-15-MSRP-PCTA · CFDA 12.420 · Discretionary

DoD Multiple Sclerosis Pilot Clinical Trial Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
September 10, 2015
Close date
3
Expected awards

The verdict

DoD Multiple Sclerosis Pilot Clinical Trial Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 3 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
3
expected awards
12.420
CFDA program

Archived opportunity record

DoD Multiple Sclerosis Pilot Clinical Trial A… is closed (last close September 10, 2015). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed September 10, 2015

Posted Apr 28 Closes Sep 10

Est. Total Funding

$2,900,000

Expected Awards

3

Instrument

Grant

Description

The MSRP Pilot Clinical Trial Award (PCTA) mechanism is being offered for the first time in FY15. The PCTA supports early-phase, proof-of-principle clinical trials to investigate hypothesis-based, innovative interventions that have the potential to result in a profound impact on management of MS symptoms. While therapeutic approaches proposed for testing through the PCTA must represent novel, hypothesis-based, “outside-the-box” approaches for treating MS symptoms, they may include therapies already in clinical use, or undergoing clinical testing, for other diseases, provided that the proposed use for MS would lead to a major advancement for treating one of the disease symptoms. It is anticipated that outcomes from studies funded by this award will provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform MS patient care. The PCTA will support clinical trials encompassing Phase 0, Phase I, or pilot Phase II for drugs or drug combinations, Class II or III for devices, or other types of trials that conduct early clinical testing of innovative approaches for MS symptoms. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Principal Investigators (PIs) seeking funding for a preclinical research project should consider the Investigator-Initiated Research Award (W81XWH-15-MSRP-IIRA). The term “human subjects” is used in this Program Announcement/Funding Opportunity to refer to individuals who will be recruited for or who will participate in the proposed pilot clinical trial. For more information, a Human Subject Resource Document is provided at https://ebrap.org/eBRAP/public/Program.htm. Examples of acceptable studies include but are not limited to the following: • Identification of an appropriate population for the proposed study • Identification of the dosage, duration, and/or delivery strategy of an intervention • Evaluation of the feasibility of the intervention in MS • Evaluation of efficacy and safety The following are important aspects of submission for the PCTA: • Pre-application is required; application submission is by invitation only. • The application must include scientific rationale and/or preliminary data relevant to MS and the proposed study. • The proposed intervention to be tested should offer significant potential impact on the management of MS symptoms. • The application should demonstrate documented availability of, and access to, a suitable patient population that will support a meaningful outcome for the study. • The application should clearly describe the steps that will be taken to advance the intervention into the next stage of development following the conclusion of this award. • Preclinical studies will not be supported by this mechanism. • Investigational New Drug (IND) or Investigational Device Exemption (IDE) approvals, if applicable, must be in place before an award will be made. • Clinical trials are expected to be initiated within 6 months of the award date. Funding from the PCTA must support a clinical trial and cannot be used for preclinical research or correlative studies. Principal Investigators (PIs) seeking funding for preclinical or correlative studies should refer to the FY15 MSRP Investigator-Initiated Research Award mechanism (Funding Opportunity Number: W81XWH-15-MSRP-IIRA).

Catch-all / unrestricted eligibility mark · W81XWH-15-MSRP-PCTA

Grants.gov marks DoD Multiple Sclerosis Pilot Clinical Trial A… with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

CDMRP Help Desk 301-682-5507

What to do next

DoD Multiple Sclerosis Pilot Clinical Trial A… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants